Mark Crowther

McMaster University & St Joseph's Hospital, Canada

Mark Crowther M.D., MSc., FRCPC

Academic positions:
- Professor and Division Director, Hematology (McMaster University)
- Director of Laboratory Hematology (Hamilton Regional Laboratory Medicine Program)
- Head of Service, Hematology (St. Joseph's Healthcare, Hamilton)
- Senior Clinical Research Advisor (Father Sean O'Sullivan Research Centre)

All industry positions (in last five years):

Research interests:
Dr Crowther's current research interests include exploring ways of improving the way that we use our current anticoagulant drugs; foci include exploring the use of vitamin K to treat warfarin-associated coagulopathy, the use of low molecular weight heparin in patients with renal failure, and studies which explore why patients with end-stage renal disease suffer blood clotting complications.

Any other information:

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Hematology > Bleeding & Coagulation Disorders (since 11 November 2005)

Links

http://www.fhs.mcmaster.ca/medicine/hematology/index.htm

All recent recommendations

• 6.0
  Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
  Recommended by Mark Crowther
  
• 6.0
  Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes.
  Recommended by Mark Crowther
  
• 3.2
  Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials.
  Recommended by Mark Crowther, Mike Murphy
  
• 3.0
  Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin.
  Recommended by Mark Crowther
  
• 4.8
  D-dimer testing to determine the duration of anticoagulation therapy.
  Recommended by Frederick Spencer, Mark Crowther
  
• 3.0
  The effect of low molecular weight heparin on survival in patients with advanced malignancy.
  Recommended by Mark Crowther